ZA Biomedical, a bio-pharmaceutical enterprise based in Zhongshan's Torch High-Tech Zone, has closed its A+ funding round. The capital will fuel its future clinical development and global expansion.

The funds will primarily support Phase I (healthy volunteer) and Phase II clinical trials of ZA001 ointment, alongside securing the US FDA IND approval for condyloma acuminatum treatment. This proprietary ointment, developed in-house, addresses multiple indications including HPV/HSV-related diseases, actinic keratosis, and multidrug-resistant bacterial infections.

Founded in 2018 by three immunology PhDs with over 20 years' expertise, the company established operations at the National Health Technology Park in June 2022. Specializing in therapeutic vaccines and peptide therapeutics, it focuses on oncology, drug-resistant skin infections, and HPV-related conditions. The firm previously completed its Series A financing in September 2023.

Leveraging a world-class scientific team in oncology and HPV therapy, ZA Biomedical has forged strategic partnerships with leading pharmaceutical developers. Its pipeline now includes five Class 1 novel drugs and a therapeutic cervical cancer vaccine in active development.